A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant chemo-radiotherapy with weekly cisplatin for at least five weeks.
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Dexamethasone
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2017 New trial record